Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Mpoudi-Etame M, Tovar Sanchez T, Bousmah MA, Omgba Bassega P, Olinga J, Mimbe E, Foalem M, Chiep C, Edimo S, Varloteaux M, Pelloquin R, Lamare N, Boyer S, Peeters M, Reynes J, Calmy A, Hill A, Delaporte E, Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group. Mpoudi-Etame M, et al. Among authors: kouanfack c. Open Forum Infect Dis. 2023 Nov 20;10(12):ofad582. doi: 10.1093/ofid/ofad582. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38156046 Free PMC article.
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E. Laurent C, et al. Among authors: kouanfack c. Lancet. 2004 Jul 3-9;364(9428):29-34. doi: 10.1016/S0140-6736(04)16586-0. Lancet. 2004. PMID: 15234853 Clinical Trial.
Antiretroviral drug resistance and routine therapy, Cameroon.
Laurent C, Kouanfack C, Vergne L, Tardy M, Zekeng L, Noumsi N, Butel C, Bourgeois A, Mpoudi-Ngolé E, Koulla-Shiro S, Peeters M, Delaporte E. Laurent C, et al. Among authors: kouanfack c. Emerg Infect Dis. 2006 Jun;12(6):1001-4. doi: 10.3201/eid1206.050860. Emerg Infect Dis. 2006. PMID: 16707062 Free PMC article.
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene YM, Essomba C, Calmy A, Mpoudi-Ngolé E, Delaporte E, Koulla-Shiro S; French National Agency for Research on AIDS 1274 Study Group. Kouanfack C, et al. J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):216-9. doi: 10.1097/QAI.0b013e3181743955. J Acquir Immune Defic Syndr. 2008. PMID: 18520681 Free article.
Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.
Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, Delaporte E. Kouanfack C, et al. Clin Infect Dis. 2009 May 1;48(9):1318-22. doi: 10.1086/597779. Clin Infect Dis. 2009. PMID: 19320592
129 results